Liver and Pancreatic Cancer

Treatment Care

Liver and Pancreatic Cancer Hospital in Banjara Hills, Hyderabad

Hepatobiliary and Pancreatic Cancers

Liver, Gall Bladder and Pancreatic Cancers

At Horizon Cancer Centre we combine high-resolution imaging, molecular profiling, advanced hepatobiliary surgery, interventional oncology, and modern systemic therapies to deliver evidence-based, biology-driven care.

Liver Cancer

These cancers often remain silent until advanced. Mild abdominal discomfort, jaundice, unexplained weight loss, or altered liver function tests are frequently ignored.

Types

Hepatocellular carcinoma

Intrahepatic Cholangiocarcinoma

Secondary (metastatic) liver tumors

Common Risk Factors

Chronic Hepatitis B & C

Cirrhosis

NAFLD/NASH

Alcohol-related liver disease

Advanced Management Strategy with focus on organ preservation

For Early Stage Disease

Anatomic or parenchyma-sparing liver resection

Laparoscopic liver surgery where feasible

Radiofrequency ablation / Microwave ablation

Liver transplant referral
Intermediate Stage
For Advanced / Metastatic Disease we offer Systemic Therapy

Atezolizumab + Bevacizumab (first-line standard in eligible patients)

Durvalumab ± tremelimumab protocol

Sorafenib

Lenvatinib
Molecular & Genetic Evaluation

MSI testing (selected cases)

FGFR2, IDH1 mutations (cholangiocarcinoma)

Hepatitis status & viral load

Cirrhosis severity scoring

Gall Bladder Cancer

Warning Signs

Persistent right upper abdominal pain

Jaundice

Unexplained weight loss

Thickened gall bladder on imaging

Treatment Approach at HCC

For Early Incidental Disease we offer

Extended radical cholecystectomy

Liver wedge resection

Regional lymphadenectomy
Locally Advanced Disease
Systemic Therapy

Gemcitabine + Cisplatin backbone

Durvalumab in advanced biliary tract cancers

Targeted therapy in FGFR2 / IDH1 mutated cholangiocarcinoma
Genetic & Risk Assessment

Family history review

Chronic gallstones & inflammation risk correlation

Lynch syndrome screening in select patients

Pancreatic Cancer

Pancreatic cancer requires early suspicion and aggressive multidisciplinary care. We have two different types of cell groups in the pancreatic gland. So two distinct forms of cancers occur.

Exocrine Pancreatic Cancer (Pancreatic Adenocarcinoma)

This accounts for ~85–90% of cases.
All pancreatic cancer patients are offered germline mutation evaluation where appropriate.

Symptoms

Painless jaundice

Back pain

New-onset diabetes in older adults

Significant weight loss
Surgical Options

Whipple procedure (Pancreaticoduodenectomy)

Distal pancreatectomy with splenic preservation when oncologically safe

Vascular resection & reconstruction in borderline resectable disease
Neoadjuvant & Adjuvant Therapy
For Advanced & Metastatic Disease – Precision Therapy

Olaparib (BRCA-mutated maintenance therapy)

Pembrolizumab (MSI-H tumors)

NTRK fusion targeted therapy where applicable
Genetic Testing – Mandatory in Many Patients

Pancreatic Neuroendocrine Tumors (Endocrine Tumors)

Less common, biologically distinct, often slower growing.

Types

Functional (insulinoma, gastrinoma)

Non-functional tumors
Management Strategy

Surgical resection

Enucleation for small functional tumors

Everolimus

Sunitinib

Peptide receptor radionuclide therapy (PRRT) in selected cases
Molecular Considerations

Our Hepatobiliary–Pancreatic Cancer Model at HCC

We integrate:

High-quality imaging staging

Molecular-guided therapy

Organ-function preservation

Nutrition & metabolic optimisation

Long-term survivorship planning

FAQ’s

1.What are the early symptoms of liver cancer?

Early liver cancer may not cause clear symptoms. Warning signs include:
• Persistent right upper abdominal discomfort
• Unexplained weight loss
• Fatigue
• Worsening liver function in known cirrhosis
• New abdominal swelling
In patients with hepatitis B, C, or cirrhosis, routine surveillance with ultrasound and AFP testing is critical.
2. Is liver cancer curable?

Yes — if detected early.
Curative options include:
• Surgical resection
• Liver transplantation (in selected criteria-based patients)
• Ablation therapies
Advanced disease is often managed with immunotherapy-based systemic treatment to control progression and prolong survival.
3. What is the survival rate of pancreatic cancer?

Pancreatic cancer outcomes depend entirely on stage at diagnosis.
• Early resectable disease has significantly better outcomes with surgery + chemotherapy.
• Borderline tumors benefit from neoadjuvant therapy before surgery.
• Advanced disease is treated with modern chemotherapy and biomarker-guided therapy.
Early evaluation of symptoms such as painless jaundice or new-onset diabetes after age 50 is crucial.
4. Should all pancreatic cancer patients undergo genetic testing?

Yes — current international guidelines recommend germline genetic testing for most patients with pancreatic adenocarcinoma.
Genes commonly tested:
• BRCA1 / BRCA2
• PALB2
• Lynch syndrome genes
Mutation-positive patients may benefit from targeted therapy such as Olaparib.
5. What is the difference between exocrine and endocrine pancreatic tumors?

• Exocrine tumors (adenocarcinoma) are more common and aggressive.
• Neuroendocrine (endocrine) tumors are less common, often slower growing, and treated differently.
Neuroendocrine tumors may respond to targeted drugs like Everolimus/sunitinib or long acting Octreotide preparations
6. Can gall bladder cancer be detected early?
7. Is immunotherapy effective in liver and biliary cancers?

Yes — immunotherapy has changed the standard of care in advanced disease.
Examples include:
• Atezolizumab + Bevacizumab for advanced hepatocellular carcinoma
• Durvalumab for advanced biliary tract cancers
Treatment is personalized based on liver function, staging, and molecular profile.
8. Can pancreatic cancer present as diabetes?

When Should You Seek Evaluation?

Persistent jaundice

Unexplained weight loss

Chronic liver disease with new symptoms

Family history of pancreatic or liver cancer

New-onset diabetes after age 50 need structured follow-up

Reviewed By

Medically Reviewed by : Dr. Srinivas Prasad, MCh (Surgical Oncology)
20+ years of experience in oncologic surgery and multidisciplinary cancer care.
Registration No: 2111
Last reviewed: February 2026